1. Home
  2. EDIT
  3. EDIT News

Latest Editas Medicine Inc. (EDIT) News on May 10, 2025

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
EDIT

GlobeNewswire

4 days ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
EDIT

GlobeNewswire

11 days ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

EDIT

MT Newswires

12 days ago

HC Wainwright Initiates Coverage on Editas Medicine With Buy Rating, $3 Price Target

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year
EDIT

Simply Wall St.

17 days ago

Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?
EDIT

Zacks

a month ago

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

AstraZeneca deepens China investment; Editas loses CFO to Dyne
EDIT

BioPharma Dive

2 months ago

AstraZeneca deepens China investment; Editas loses CFO to Dyne

EDIT

MT Newswires

2 months ago

Dyne Therapeutics Names Erick Lucera as CFO

Editas Medicine Announces Chief Financial Officer Transition
EDIT

GlobeNewswire

2 months ago

Editas Medicine Announces Chief Financial Officer Transition

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely
EDIT

Simply Wall St.

2 months ago

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
EDIT

Zacks

2 months ago

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
EDIT

Zacks

2 months ago

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

EDIT

Associated Press Finance

2 months ago

Editas: Q4 Earnings Snapshot

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
EDIT

GlobeNewswire

2 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
EDIT

GlobeNewswire

3 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
EDIT

Zacks

3 months ago

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Editas Medicine Outlines 2025 Strategic Priorities and Milestones
EDIT

TipRanks

4 months ago

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
EDIT

Zacks

4 months ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
EDIT

GlobeNewswire

4 months ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
EDIT

Zacks

4 months ago

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
EDIT

GlobeNewswire

4 months ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?
EDIT

Insider Monkey

4 months ago

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
EDIT

Zacks

5 months ago

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

EDIT

MT Newswires

5 months ago

JPMorgan Downgrades Editas Medicine to Underweight From Neutral

Editas Medicine price target lowered to $8 from $10 at Baird
EDIT

TipRanks

5 months ago

Editas Medicine price target lowered to $8 from $10 at Baird

EDIT

Investing.com

5 months ago

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts
EDIT

GuruFocus.com

5 months ago

Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts

EDIT

MT Newswires

5 months ago

JonesTrading Downgrades Editas Medicine to Hold From Buy

EDIT

MT Newswires

5 months ago

Stifel Downgrades Editas Medicine Hold From Buy, Adjusts Price Target to 3 From $11

EDIT

MT Newswires

5 months ago

Truist Securities Downgrades Editas Medicine Hold From Buy

EDIT

MT Newswires

5 months ago

RBC Cuts Price Target on Editas Medicine to $4 From $5, Keeps Sector Perform, Speculative Risk

EDIT

MT Newswires

5 months ago

Truist Downgrades Editas Medicine to Hold From Buy, Removes $8 Price Target

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
EDIT

Benzinga

5 months ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

EDIT

MT Newswires

5 months ago

Editas Medicine Focuses on In Vivo Gene-Editing Medicines, Ends Reni-Cel Development to Cut Costs

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
EDIT

GlobeNewswire

5 months ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas to lay off staff after search for sickle cell partner comes up empty
EDIT

BioPharma Dive

5 months ago

Editas to lay off staff after search for sickle cell partner comes up empty

EDIT

MT Newswires

5 months ago

Wells Fargo Downgrades Editas Medicine to Equal Weight From Overweight, Cuts Price Target to $4 From $7

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
EDIT

Zacks

5 months ago

Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

EDIT

MT Newswires

5 months ago

Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
EDIT

GlobeNewswire

5 months ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?
EDIT

Zacks

5 months ago

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

Editas Medicine downgraded to Underperform from Buy at BofA
EDIT

TipRanks

5 months ago

Editas Medicine downgraded to Underperform from Buy at BofA

EDIT

MT Newswires

5 months ago

BofA Securities Downgrades Editas Medicine to Underperform

Editas Medicine to Participate in Upcoming Investor Conferences
EDIT

GlobeNewswire

6 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%
EDIT

Simply Wall St.

6 months ago

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty
EDIT

GuruFocus.com

6 months ago

Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
EDIT

Zacks

6 months ago

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
EDIT

Zacks

6 months ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations
EDIT

Simply Wall St.

6 months ago

Editas Medicine Third Quarter 2024 Earnings: Misses Expectations

EDIT

MT Newswires

6 months ago

Raymond James Downgrades Editas Medicine to Market Perform From Outperform

EDIT

MT Newswires

6 months ago

Truist Securities Adjusts Editas Medicine's Price Target to $8 From $12, Keeps Buy Rating

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
EDIT

Zacks

6 months ago

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

EDIT

Associated Press Finance

6 months ago

Editas: Q3 Earnings Snapshot

Editas Medicine Announces Third Quarter 2024 Results and Business Updates
EDIT

GlobeNewswire

6 months ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?
EDIT

Insider Monkey

6 months ago

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
EDIT

Zacks

6 months ago

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline
EDIT

Zacks

6 months ago

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
EDIT

Zacks

7 months ago

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
EDIT

Zacks

7 months ago

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

EDIT

MT Newswires

7 months ago

Chardan Cuts Price Target on Editas Medicine to $12 From $20, Keeps Buy Rating

Editas and Genevant team up to develop gene editing therapies
EDIT

Pharmaceutical Technology

7 months ago

Editas and Genevant team up to develop gene editing therapies

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
EDIT

Zacks

7 months ago

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

EDIT

MT Newswires

7 months ago

Editas Medicine Achieves Proof of Concept for In Vivo Gene Editing of Hematopoietic Stem Cells in Humanized Mice

Editas, changing course again, looks to partner lead CRISPR therapy
EDIT

BioPharma Dive

7 months ago

Editas, changing course again, looks to partner lead CRISPR therapy

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
EDIT

GlobeNewswire

7 months ago

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

EDIT

MT Newswires

7 months ago

Editas Medicine, Genevant Partner to Develop mRNA-LNP Gene Editing Therapeutics

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
EDIT

GlobeNewswire

7 months ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
EDIT

GlobeNewswire

7 months ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings
EDIT

GuruFocus.com

7 months ago

State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings

Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company
EDIT

Simply Wall St.

7 months ago

Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the company

Editas Medicine Secures $57M Deal for Gene-Editing Technology
EDIT

TipRanks

7 months ago

Editas Medicine Secures $57M Deal for Gene-Editing Technology

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m
EDIT

Pharmaceutical Technology

7 months ago

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

EDIT

MT Newswires

7 months ago

National Bank on DRI Healthcare's Casgevy Stream Acquisition

Editas trades Vertex fees for upfront cash in DRI deal
EDIT

BioPharma Dive

7 months ago

Editas trades Vertex fees for upfront cash in DRI deal

EDIT

MT Newswires

7 months ago

DRI Healthcare Trust Buying Payment Streams Based On Gene-Editing Technology For US$57 Million

EDIT

MT Newswires

7 months ago

Editas Medicine Sells Future License Fees for Gene-Editing Technology for $57 Million

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
EDIT

GlobeNewswire

7 months ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

EDIT

MT Newswires

8 months ago

JonesTrading Initiates Editas Medicine at Buy With $13 Price Target

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?
EDIT

Zacks

8 months ago

Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?

Editas Medicine to Participate in Upcoming Investor Conferences
EDIT

GlobeNewswire

8 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
EDIT

Simply Wall St.

9 months ago

We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
EDIT

Zacks

9 months ago

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

EDIT

MT Newswires

9 months ago

BofA Securities Upgrades Editas Medicine to Buy From Neutral

EDIT

MT Newswires

9 months ago

Truist Securities Adjusts Price Target on Editas Medicine to $12 From $20, Maintains Buy Rating

EDIT

Thomson Reuters StreetEvents

9 months ago

Q2 2024 Editas Medicine Inc Earnings Call

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
EDIT

Zacks

9 months ago

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

EDIT

Associated Press Finance

9 months ago

Editas: Q2 Earnings Snapshot

Editas Medicine Announces Second Quarter 2024 Results and Business Updates
EDIT

GlobeNewswire

9 months ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
EDIT

GlobeNewswire

9 months ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

EDIT

MT Newswires

10 months ago

RBC Cuts Price Target on Editas Medicine to $8 From $11, Keeps Sector Perform, Speculative Risk

Editas Medicine (NASDAQ:EDIT) investors are sitting on a loss of 90% if they invested three years ago
EDIT

Simply Wall St.

10 months ago

Editas Medicine (NASDAQ:EDIT) investors are sitting on a loss of 90% if they invested three years ago

Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?
EDIT

Insider Monkey

10 months ago

Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?

What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?
EDIT

Insider Monkey

10 months ago

What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
EDIT

Zacks

a year ago

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

EDIT

MT Newswires

a year ago

Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
EDIT

GlobeNewswire

a year ago

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
EDIT

GlobeNewswire

a year ago

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Lotto 6/49 - $64 million up for grabs in the next draw!
EDIT

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
EDIT

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
EDIT

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
EDIT

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Share on Social Networks: